Haemonetics Q4 revenue falls 3.7% as EPS rises to $1.17; sets $20M restructuring
Haemonetics reported fourth-quarter fiscal 2025 revenue of $330.6 million, down 3.7% from a year earlier, while GAAP earnings per diluted share rose to $1.17 from $0.40 and adjusted EPS rose 37.8% to $1.24. The company also issued fiscal 2026 guidance, including adjusted EPS of $4.70 to $5.00, and approved a market and regional alignment initiative expected to bring about $20 million in restructuring charges and about $30 million in annualized savings.
Key points
- Q4 fiscal 2025 revenue $330.6 million, down 3.7%; organic revenue down 0.2%, with Plasma down 9.1% and Blood Center down 22.2%
- Q4 GAAP EPS $1.17 vs $0.40; adjusted EPS $1.24, up 37.8%
- Fiscal 2026 guidance: adjusted EPS $4.70 to $5.00, adjusted operating margin 26% to 27%, free cash flow $160 million to $200 million
- Alignment initiative: about $20 million in charges, mostly cash, through fiscal 2027; about $30 million annualized savings once complete
The filing
Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.